Sort
15,273 grants matching “antimicrobial resistance”
Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria
$300,000Assad Kazeminy · Ajk Biopharmaceutical Llc · R41 · FY2022 · AI
Antimetabolites for Acute Myeloid Leukemias
$300,000Dennis L Wright · Quercus Molecular Design, Llc · R41 · FY2020 · CA
An immunotherapeutic to prevent gonorrhea
$300,000Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2019 · AI
Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae
$300,000Reen Wu · Effectorbio, Inc. · R43 · FY2023 · AI
Antibiotic Use Data Collection in U.S. Poultry and Swine Production
$300,000Randall S Singer · Mindwalk Consulting Group, Llc · U01 · FY2016 · FD
A highly multiplexed convection flow qPCR assay and platform delivering rapid, comprehensive identification and predictive AST of pathogens causing UTIs.
$300,000Dmitriy Khodakov · Torus Biosystems, Inc. · R43 · FY2021 · AI
A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
$300,000Rainer Ng · Baebies, Inc. · R44 · FY2025 · AI
Heme Oxygenase: Structure, function and pathogenesis
$300,000Angela None Wilks · University Of Maryland Baltimore · R56 · FY2010 · AI
Next-day whole genome sequencing and analysis using nanopore sequencing for real-time outbreak and transmission determination in healthcare facilities
$300,000Mohamad Sater · Day Zero Diagnostics, Inc. · R43 · FY2021 · AI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
$300,000Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R43 · FY2024 · AI
DMS-EPSRC Eco-Evolutionary Dynamics of Fluctuating Populations
$300,000Uwe C Tauber · Virginia Polytechnic Institute And State University · · FY2021 · MPS
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa
$300,000Timothy J Opperman · Microbiotix, Inc · R41 · FY2021 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections
$300,000Laurel McGrane · Fimbrion Therapeutics, Inc. · R43 · FY2024 · AI
Applied Research in Antimicrobial Resistance: Studies of Susceptibility Testing
$300,000Lisa Saiman · Columbia University Health Sciences · R01 · FY2007 · CI
Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections
$300,000Joshua G. Pierce · Synoxa Sciences, Inc · R41 · FY2020 · AI
SBIR PA22-176 - Culture-free microbial enrichment for diagnosis and characterization of anti-microbial resistance
$300,000Sandeep Kasoji · Triangle Biotechnology, Inc. · R43 · FY2023 · IP
Combining benchmarking and Competency-based training to implement antimicrobial stewardship on dairy farms
$300,000Pamela L Ruegg · Michigan State University · U01 · FY2022 · FD
Novel Antibiotics from Marine Invertebrate Microbes
$300,000Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R43 · FY2018 · AI
Antifungal Dermal Templates for Wound Healing
$300,000Manav Mehta · Gel4med, Inc. · R43 · FY2020 · AI
Antibiotic Use Data Collection in U.S. Poultry and Swine Production
$300,000Randall S Singer · Mindwalk Consulting Group, Llc · U01 · FY2017 · FD
FLAVOBACTERIUM COLUMNARE IS RECOGNIZED AS ONE OF THE MOST IMPORTANT ENDEMIC PATHOGENS OF FARMED FISH IN THE USA. OUTBREAKS OF COLUMNARIS HAVE OCCURRED IN ALL STATES WHERE FRESH WATER FISH ARE CULTURED FOR HUMAN CONSUMPTION, AS WELL AS IN ORNAMENTAL SPECIES AND WILD FISH. A LACK OF EFFICACIOUS VACCINES, MOUNTING ANTIMICROBIAL RESISTANCE, AND LIMITED TREATMENT OPTIONS HAVE LED TO FISH KILLS APPROACHING 90% MORTALITY IN SOME US EPIZOOTICS. DIRECT ECONOMIC LOSSES ARE COMPOUNDED BY THE COSTS OF DELAYED PRODUCTION AND GROWTH, CHEMOTHERAPEUTANTS AND ADDED LABOR. FURTHERMORE, WHEN ANTIBIOTIC THERAPY IS ATTEMPTED, TREATMENT FAILURE IS COMMON. A LACK OF HOST SPECIFICITY POSES AN ADDITIONAL RISK, SHOULD THE PATHOGEN BE RELEASED INTO NATURAL HABITATS. THESE FACTORS ILLUSTRATE THAT PREVENTION THROUGH VACCINATION OFFERS SIGNIFICANT ADVANTAGES OVER TREATMENT. IN THIS PROPOSAL, THREE ESTABLISHED AQUATIC ANIMAL HEALTH LABORATORIES WILL PARTNER TO INVESTIGATE THE ANTIGENIC DIVERSITY OF F. COLUMNARE GENETIC GROUPS IN THREE IMPORTANT AQUACULTURED FISH SPECIES IN THE USA (E.G., RAINBOW TROUT, CHANNEL CATFISH, NILE TILAPIA). THE OVERARCHING GOAL OF THIS STUDY IS TO IDENTIFY SHARED IMMUNOGENIC PROTEIN VACCINE ANTIGENS OF F. COLUMNARE TO PROVIDE PROTECTION AGAINST EACH GENETIC GROUP REPORTED IN THE US. THIS RESEARCH WILL LEAD TO AN IMPROVED UNDERSTANDING OF THE EPIZOOTIOLOGY AND ANTIGENIC DIVERSITY OF THE PATHOGEN, AND THE DEVELOPMENT OF EFFECTIVE SUBUNIT VACCINE(S) TO PREVENT COLUMNARIS DISEASE. ADDITIONAL BENEFITS INCLUDE AN INCREASED KNOWLEDGE OF IMMUNE RESPONSES IN TELEOST FISH AND PATHOGENESIS OF BACTERIAL FISH PATHOGENS, AS WELL AS ADVANCES IN FISH VACCINOLOGY, ALL EXTREMELY RELEVANT TO DISEASE CONTROL IN AQUACULTURE.
$300,000University Of California, Davis · · FY2019 · National Institute of Food and Agriculture
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections
$300,000Carl Neil Kraus · Arrevus, Inc. · R41 · FY2018 · AI
UroLogic: Rapid, Near-to-Care Identification and Antimicrobial Susceptibility Testing of Microbes in Urine Specimens from Outpatients with Suspected Urinary Tract Infection
$300,000Bernard M Churchill · Microbedx, Inc. · R43 · FY2018 · AI
Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds
$300,000Eva Garland · Agile Sciences, Inc. · R41 · FY2011 · AI
Using combinations of single-cell phenotypes for rapid antibiotic susceptibility testing
$300,000Kwangmin Son · Phast Corporation · R43 · FY2020 · AI